Tissue Regenix Group plc announced the launch of its new BioRinse® product line for all sports medicine allografts that Tissue Regenix distributes in the US and internationally. The Company's BioRinse sterilisation technology platform uses proprietary processes to produce sterile bone and soft tissue products. The new process for sports medicine allografts causes less damage to the tissue in order to produce an enhanced sterile soft tissue product.

The primary market for these grafts is sports medicine, mainly consisting of tendon and ligament reconstruction procedures in the knee, ankle, elbow, and other joints. The Company has previously discussed plans to innovate the processing protocols for its soft tissue products in order to enhance performance, efficiency, and safety in the products that Tissue Regenix already produces for the sports medicine market. These changes will allow Tissue Regenix to capture a larger segment of the estimated USD 300 million market for allograft soft tissue tendons for ligament reconstruction procedures of the knee.